GSK (LON:GSK) Insider Buys £108.55 in Stock

GSK plc (LON:GSK) insider Julie Brown purchased 5 shares of the stock in a transaction on Monday, April 13th. The shares were acquired at an average price of GBX 2,171 per share, for a total transaction of £108.55.

Julie Brown also recently made the following trade(s):

• On Tuesday, February 10th, Julie Brown purchased 6 shares of GSK stock. The shares were acquired at an average price of GBX 2,179 per share, for a total transaction of £130.74.

GSK Price Performance

GSK stock traded up GBX 20 during mid-day trading on Tuesday, reaching GBX 2,190. 5,034,690 shares of the company’s stock were exchanged, compared to its average volume of 9,384,402. The company has a market cap of £87.53 billion, a price-to-earnings ratio of 15.78, a price-to-earnings-growth ratio of 1.24 and a beta of 0.35. The stock’s 50 day moving average is GBX 2,105.91 and its 200 day moving average is GBX 1,885.52. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. GSK plc has a 12-month low of GBX 1,263.50 and a 12-month high of GBX 2,282.

GSK (LON:GSK) last issued its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a return on equity of 37.19% and a net margin of 17.50%. On average, research analysts expect that GSK plc will post 175.980975 EPS for the current year.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK expanded its share buyback, repurchasing 325,000 ordinary shares and lifting treasury holdings to about 6.36% of voting rights — a direct capital-return move that reduces float and supports EPS. GSK Expands Share Buyback, Lifts Treasury Holdings to 6.36% of Voting Rights
• Positive Sentiment: GSK reported positive Phase I BEHOLD‑1 results for Mo‑Rez (candidate for ovarian and endometrial cancer), which increases the drug’s development and commercial upside if later‑stage trials confirm benefit. This pipeline news can lift long‑term valuation expectations. GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez
• Positive Sentiment: Jefferies reaffirmed its “buy” rating on GSK and kept a GBX 2,500 price target — a supportive analyst signal that may attract buyer interest given the gap to the current share price. Broker Views (Jefferies reaffirmation)
• Neutral Sentiment: Several senior executives acquired shares under a company reward plan (routine/expected insider participation). Such transactions are typically neutral-to-modestly positive for sentiment but not large enough to materially move valuation by themselves. GSK Executives Acquire Shares Under Company Reward Plan
• Neutral Sentiment: Insider purchase: Julie Brown bought 5 shares at ~GBX 2,171. The size is immaterial for float but signals management confidence at a personal level. (No article link provided.)
• Negative Sentiment: Aggregate broker coverage remains cautious overall — GSK received an average “Hold” rating from brokerages, which could cap upside if the market looks for broader analyst upgrades beyond isolated buy calls. GSK plc (LON:GSK) Receives Average Rating of “Hold” from Brokerages

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Shore Capital Group restated a “buy” rating on shares of GSK in a research report on Wednesday, March 25th. Berenberg Bank restated a “hold” rating and issued a GBX 2,000 target price on shares of GSK in a research report on Thursday, March 26th. Citigroup raised their target price on GSK from GBX 1,900 to GBX 2,250 and gave the company a “buy” rating in a research report on Monday, February 9th. Jefferies Financial Group restated a “buy” rating and issued a GBX 2,500 target price on shares of GSK in a research report on Tuesday. Finally, JPMorgan Chase & Co. restated an “underweight” rating on shares of GSK in a research report on Wednesday, January 7th. Three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, GSK currently has a consensus rating of “Hold” and an average target price of GBX 2,023.57.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.